SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-256103
Filing Date
2023-10-13
Accepted
2023-10-13 16:16:01
Documents
13
Period of Report
2023-10-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d424554d8k.htm   iXBRL 8-K 25126
2 EX-99.1 d424554dex991.htm EX-99.1 480454
  Complete submission text file 0001193125-23-256103.txt   759210

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mirm-20231013.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mirm-20231013_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mirm-20231013_pre.xml EX-101.PRE 11709
7 EXTRACTED XBRL INSTANCE DOCUMENT d424554d8k_htm.xml XML 3470
Mailing Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404
Business Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 650-667-4085
Mirum Pharmaceuticals, Inc. (Filer) CIK: 0001759425 (see all company filings)

IRS No.: 831281555 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38981 | Film No.: 231325248
SIC: 2834 Pharmaceutical Preparations